Schering Corporation

Stephen Tindall

Nicholas J Murgolo

Paul J Zavodny

Barbara Dalie

Kenneth Miller

Paul Reichert

Alan W Hruza

Chuan-Chu Chou

Hung V Le

William T Windsor

John S Abrams

Charles W McNemar

Chung-Her Jenh

Hanh Nguyen

Mary E Petro

Jon E Silver

Tattanahalli L Nagabhushan

Nagamani Nagabhushan

Tattanahalli L Nagahhushan

Nagamani Nagahhushan

A monoclonal antibody is provided which specifically binds to human interleukin-5. Also provided are a hybridoma which produces the monoclonal antibody; complementary DNAs which encode the heavy and light chain variable regions of the monoclonal antibody and CDRs therefrom; humanized monoclonal antibodies; and pharmaceutical compositions comprising the monoclonal antibody or anti-idiotypic antibodies directed against it, humanized monoclonal antibodies, binding fragments, binding compositions or single-chain binding proteins derived from the antibody and a physiologically acceptable carrier.

Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Humanized monoclonal antibodies against human interleukin-5

Humanized monoclonal antibodies against human interleukin-4

Monoclonal antibodies are provided which are specific for human interleukin-4. Also provided are complementary DNAs which encode the heavy and light chain variable regions of such monoclonal antibodies and complementarity determining regions from such DNAs; and kits and methods for detecting, measuring and immunopurifying human interleukin-4, and for blocking the biological activity of human interleukin-4.

Cloning and exprssion of humanized monoclonal antibodies against human

A method for producing a crystalline zinc interferon (IFN) .alpha.-2 comprising forming a soluble solution of IFN .alpha.-2 and a metal acetate salt under condtions wherein supersaturation and metal alpha interferon crystals occur.

Method for producing metal-interferon-.alpha. crystals

Humanized monoclonal antibodies are provided which are specific for human IL-4 and have properties unexpectedly superior to other, previously available humanized antibodies. Also provided are nucleic acids which encode the heavy and light chain variable regions of such monoclonal antibodies or antigenic fragments thereof; anti-idiotypic antibodies; and methods for detecting, measuring and immunopurifying human IL-4, and for blocking or mimicking the biological activity of human IL-4.

The present invention provides for crystalline zinc-interferon alfa-2 (IFN .alpha.-2) having a monoclinic morphology. The present invention further provides for crystalline cobalt-IFN .alpha.-2, crystalline calcium-IFN .alpha.-2, and crystalline IFN .alpha.-2 having a serum half-life of at least about 12 hours when injected into a primate. The present invention further provides for a method for producing a crystalline IFN .alpha.-2 comprising forming a soluble metal-IFN .alpha.-2 complex, and equilibrating the soluble metal-IFN .alpha.-2 complex in solution with an acetate salt of the metal under conditions that will cause the metal-IFN .alpha.-2 solution to become supersaturated and form crystalline metal-IFN .alpha.-2. The present invention also includes crystalline metal-alfa interferon having monoclinic, plate and needle morphologies.

Metal-interferon-alpha crystals

Growing community of inventors

Madison, NJ, United States of America

Stephen Tindall